

# EFFECT OF IMMUNOTHERAPY DRUG SACITUZUMAB GOVITECAN ON TRIPLE-NEGATIVE BREAST CANCER

## Triple-negative breast cancer (TNBC)

Aggressive and proliferates rapidly; extremely difficult to treat




Low estrogen  
receptor (ER)  
levels



Low progesterone  
receptor (PR)  
levels



No high levels of  
human epidermal  
growth factor 2  
(HER2)



SN-38 (active ingredient  
of anti-cancer drug irinotecan)

Hydrolyzable linker

Anti-trop-2 antibody

## Sacituzumab Govitecan

Targets trophoblast cell-surface antigen-2 (Trop-2) which is found only on cancer cells, thus minimizing damage to healthy cells

## Response to Sacituzumab Govitecan in IMMU-123 and ASCENT trials vs. standard chemotherapy with Pembrolizumab in ASCENT trial

- ✓ Higher response rate  
34.3% and 33.3% vs. 5.3%
- ✓ Higher progression free survival  
5.5 and 5.6 months vs. 1.7 months
- ✓ Higher overall survival  
13 and 21.1 months vs. 6.7 months
- ✓ Fewer adverse effects  
10% vs 50% neutropenia in ASCENT  
10% vs 18% diarrhea in ASCENT

## Efficacy of Sacituzumab Govitecan on TNBC



Review of studies on treatment of TNBC with Sacituzumab Govitecan, including milestone IMMU-123 and ASCENT-05 trials



**Sacituzumab  
Govitecan treatment  
shows significant  
improvement in PFS  
and tumor response  
rate for TNBC**